Departments of Medicine, University of Southern California, Los Angeles, USA.
Blood. 2010 Jan 28;115(4):887-95. doi: 10.1182/blood-2009-08-236745. Epub 2009 Nov 24.
Kaposi sarcoma-associated herpesvirus (KSHV) infection is essential to the development of Kaposi sarcoma (KS). Notch signaling is also known to play a pivotal role in KS cell survival and lytic phase entrance of KSHV. In the current study, we sought to determine whether KSHV regulates Notch components. KSHV-infected lymphatic endothelial cells showed induction of receptors Notch3 and Notch4, Notch ligands Dll4 and Jagged1, and activated Notch receptors in contrast to uninfected lymphatic endothelial cells. In addition, KSHV induced the expression of endothelial precursor cell marker (CD133) and mural cell markers (calponin, desmin, and smooth muscle alpha actin), suggesting dedifferentiation and trans-differentiation. Overexpression of latency proteins (LANA, vFLIP) and lytic phase proteins (RTA, vGPCR, viral interleukin-6) further supported the direct regulatory capacity of KSHV viral proteins to induce Notch receptors (Notch2, Notch3), ligands (Dll1, Dll4, Jagged1), downstream targets (Hey, Hes), and endothelial precursor CD133. Targeting Notch pathway with gamma-secretase inhibitor and a decoy protein in the form of soluble Dll4 inhibited growth of KSHV-transformed endothelial cell line. Soluble Dll4 was also highly active in vivo against KS tumor xenograft. It inhibited tumor cell growth, induced tumor cell death, and reduced vessel perfusion. Soluble Dll4 is thus a candidate for clinical investigation.
卡波西肉瘤相关疱疹病毒(KSHV)感染是卡波西肉瘤(KS)发生的必要条件。众所周知,Notch 信号通路在 KS 细胞存活和 KSHV 裂解期进入中也发挥着关键作用。在本研究中,我们试图确定 KSHV 是否调节 Notch 成分。与未感染的淋巴管内皮细胞相比,KSHV 感染的淋巴管内皮细胞表现出受体 Notch3 和 Notch4、Notch 配体 Dll4 和 Jagged1 的诱导,以及激活的 Notch 受体。此外,KSHV 诱导内皮前体细胞标志物(CD133)和壁细胞标志物(钙调蛋白、结蛋白和平滑肌α肌动蛋白)的表达,表明去分化和转分化。潜伏蛋白(LANA、vFLIP)和裂解期蛋白(RTA、vGPCR、病毒白细胞介素 6)的过表达进一步支持了 KSHV 病毒蛋白直接调节 Notch 受体(Notch2、Notch3)、配体(Dll1、Dll4、Jagged1)、下游靶点(Hey、Hes)和内皮前体细胞 CD133 的能力。用γ-分泌酶抑制剂和可溶性 Dll4 形式的诱饵蛋白靶向 Notch 通路,抑制了 KSHV 转化的内皮细胞系的生长。可溶性 Dll4 在体内对 KS 肿瘤异种移植物也具有高度活性。它抑制肿瘤细胞生长,诱导肿瘤细胞死亡,并减少血管灌注。因此,可溶性 Dll4 是一种有临床研究前景的候选药物。